However, Devaux et al. found that 30% of CIDP patient serum did label the nodal region and in a cell binding assay found that 24% of the CIDP patient samples had antibodies against NF186, gliomedin, neuronal cell adhesion molecule (NrCAM), and/or CNTN1 with 16% having reactivity to just one and 8% having reactivity against more than one antigen [99]. This evidence concerns the gene NRCAM and chronic inflammatory demyelinating polyradiculoneuropathy.